| Size | Price | |
|---|---|---|
| 1mg | ||
| Other Sizes |
| Targets |
Drug-linker conjugate for ADC synthesis
|
|---|---|
| ln Vitro |
The compound is characterized as a drug-linker conjugate for ADC synthesis rather than as a standalone therapeutic agent .
|
| ln Vivo |
As an ADC drug-linker conjugate intermediate, the biological activity of the final ADC molecule would depend on the specific antibody conjugated to it .
|
| Enzyme Assay |
As a drug-linker conjugate, its primary function is to serve as a synthetic intermediate for ADC production rather than as a direct biological probe.
|
| Cell Assay |
The compound is primarily a chemical intermediate for ADC synthesis, and its role in biological assays would be as part of a complete ADC molecule.
|
| References | |
| Additional Infomation |
DL-01 appears as a white to light yellow solid powder with a purity of ≥98% . Physicochemical properties include 6 hydrogen bond donors, 19 hydrogen bond acceptors, 28 rotatable bonds, and 3 defined atom stereocenters . The compound is referenced in patent WO2023046202A1 titled "Antibody, antibody-drug conjugate thereof and use thereof" by Yonghan Hu et al. . This patent likely contains the primary characterization data for the compound, including its synthesis and application in ADCs. The product has a high molecular complexity (2400), indicating a complex chemical structure typical of ADC linkers . For research applications, the compound is typically stored at -80°C for long-term stability and shipped with dry ice . This product is intended for research and development use only and is not for human or veterinary therapeutic applications .
|
| Molecular Formula |
C55H71N9O13S
|
|---|---|
| Molecular Weight |
1098.26975274086
|
| Exact Mass |
1097.4892
|
| CAS # |
2821770-49-2
|
| Related CAS # |
2964513-44-6
|
| Appearance |
White to off-white solid powder
|
| SMILES |
S(C)(C1=NC=C(C=N1)C#CCCCC(N[C@H](C(N[C@H](C(NCC(NCOCCCC1C2C=C3C(=CC=2N=C2C4=CC5=C(COC([C@@]5(CC)O)=O)C(N4CC2=1)=O)OCO3)=O)=O)CCCCN(CCC)CCC)=O)C(C)C)=O)(=O)=O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9105 mL | 4.5526 mL | 9.1052 mL | |
| 5 mM | 0.1821 mL | 0.9105 mL | 1.8210 mL | |
| 10 mM | 0.0911 mL | 0.4553 mL | 0.9105 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
